×
About 53,826 results

AllMedicine All Center

Research & Reviews  24,177 results

Grifols announces FDA approval of Xembify®, 20% subcutaneous immunoglobulin for primary immunodeficiencies
https://www.grifols.com/en/view-news/-/news/grifols-announces-fda-approval-of-xembify-20-subcutaneous-immunoglobulin-for-primary-immunodeficiencies

Jul 4th, 2019 - Grifols (MCE:GRF, MCE:GRF.P NASDAQ:GRFS), a leading global producer of plasma-derived medicines, announced today that Xembify®, its new 20% subcutaneous immunoglobulin, has been approved by the U.S. Food and Drug Administration (FDA). Xembify® is ...

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013024.pub2/full
The Cochrane Database of Systematic Reviews; Threapleton, C. et. al.

May 23rd, 2019 - Chronic obstructive pulmonary disease (COPD; including chronic bronchitis and emphysema) is a chronic respiratory condition characterised by shortness of breath, cough and recurrent exacerbations. Long‐term antibiotic use may reduce both bacterial...

Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update
http://ascopubs.org/doi/full/10.1200/JCO.18.00374
Taplitz, R. et. al.

Sep 3rd, 2018 - Antibacterial and antifungal prophylaxis is recommended for patients who are at high risk of infection, including patients who are expected to have profound, protracted neutropenia, which is defined as < 100 neutrophils/µL for > 7 days or other ri...

Optimisation of empirical antimicrobial therapy in patients with haematological maligna...
https://doi.org/10.1016/S2352-3026(17)30211-9
The Lancet. Haematology; Aguilar-Guisado M, Espigado I et. al.

Nov 20th, 2017 - Continuation of empirical antimicrobial therapy (EAT) for febrile neutropenia in patients with haematological malignancies until neutrophil recovery could prolong the therapy unnecessarily. We aimed to establish whether EAT discontinuation driven ...

Application of the MASCC and CISNE Risk-Stratification Scores to Identify Low-Risk Febr...
https://doi.org/10.1016/j.annemergmed.2016.11.007
Annals of Emergency Medicine; Coyne CJ, Le V et. al.

Jan 3rd, 2017 - Although validated risk-stratification tools have been used to send low-risk febrile neutropenic patients home from clinic and inpatient settings, there is a dearth of research evaluating these scores in the emergency department (ED). We compare t...

see more →

Guidelines  97 results

Grifols announces FDA approval of Xembify®, 20% subcutaneous immunoglobulin for primary immunodeficiencies
https://www.grifols.com/en/view-news/-/news/grifols-announces-fda-approval-of-xembify-20-subcutaneous-immunoglobulin-for-primary-immunodeficiencies

Jul 4th, 2019 - Grifols (MCE:GRF, MCE:GRF.P NASDAQ:GRFS), a leading global producer of plasma-derived medicines, announced today that Xembify®, its new 20% subcutaneous immunoglobulin, has been approved by the U.S. Food and Drug Administration (FDA). Xembify® is ...

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013024.pub2/full
The Cochrane Database of Systematic Reviews; Threapleton, C. et. al.

May 23rd, 2019 - Chronic obstructive pulmonary disease (COPD; including chronic bronchitis and emphysema) is a chronic respiratory condition characterised by shortness of breath, cough and recurrent exacerbations. Long‐term antibiotic use may reduce both bacterial...

Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by t...
https://www.idsociety.org/globalassets/idsa/practice-guidelines/2019-asymptomatic-bacteriuria.pdf

Mar 20th, 2019 - Asymptomatic bacteriuria (ASB) is a common finding in many populations, including healthy women and persons with underlying urologic abnormalities. The 2005 guideline from the Infectious Diseases Society of America recommended that ASB should be s.

Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
http://www.jnccn.org/content/16/12/1500.full
Gotlib, J.

Nov 30th, 2018 - Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocyt.

Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update
http://ascopubs.org/doi/full/10.1200/JCO.18.00374
Taplitz, R. et. al.

Sep 3rd, 2018 - Antibacterial and antifungal prophylaxis is recommended for patients who are at high risk of infection, including patients who are expected to have profound, protracted neutropenia, which is defined as < 100 neutrophils/µL for > 7 days or other ri...

see more →

Drugs  1,247 results see all →

Clinicaltrials.gov  26,651 results

Grifols announces FDA approval of Xembify®, 20% subcutaneous immunoglobulin for primary immunodeficiencies
https://www.grifols.com/en/view-news/-/news/grifols-announces-fda-approval-of-xembify-20-subcutaneous-immunoglobulin-for-primary-immunodeficiencies

Jul 4th, 2019 - Grifols (MCE:GRF, MCE:GRF.P NASDAQ:GRFS), a leading global producer of plasma-derived medicines, announced today that Xembify®, its new 20% subcutaneous immunoglobulin, has been approved by the U.S. Food and Drug Administration (FDA). Xembify® is ...

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013024.pub2/full
The Cochrane Database of Systematic Reviews; Threapleton, C. et. al.

May 23rd, 2019 - Chronic obstructive pulmonary disease (COPD; including chronic bronchitis and emphysema) is a chronic respiratory condition characterised by shortness of breath, cough and recurrent exacerbations. Long‐term antibiotic use may reduce both bacterial...

Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by t...
https://www.idsociety.org/globalassets/idsa/practice-guidelines/2019-asymptomatic-bacteriuria.pdf

Mar 20th, 2019 - Asymptomatic bacteriuria (ASB) is a common finding in many populations, including healthy women and persons with underlying urologic abnormalities. The 2005 guideline from the Infectious Diseases Society of America recommended that ASB should be s.

Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
http://www.jnccn.org/content/16/12/1500.full
Gotlib, J.

Nov 30th, 2018 - Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocyt.

Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update
http://ascopubs.org/doi/full/10.1200/JCO.18.00374
Taplitz, R. et. al.

Sep 3rd, 2018 - Antibacterial and antifungal prophylaxis is recommended for patients who are at high risk of infection, including patients who are expected to have profound, protracted neutropenia, which is defined as < 100 neutrophils/µL for > 7 days or other ri...

see more →

News  1,571 results

Grifols announces FDA approval of Xembify®, 20% subcutaneous immunoglobulin for primary immunodeficiencies
https://www.grifols.com/en/view-news/-/news/grifols-announces-fda-approval-of-xembify-20-subcutaneous-immunoglobulin-for-primary-immunodeficiencies

Jul 4th, 2019 - Grifols (MCE:GRF, MCE:GRF.P NASDAQ:GRFS), a leading global producer of plasma-derived medicines, announced today that Xembify®, its new 20% subcutaneous immunoglobulin, has been approved by the U.S. Food and Drug Administration (FDA). Xembify® is ...

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013024.pub2/full
The Cochrane Database of Systematic Reviews; Threapleton, C. et. al.

May 23rd, 2019 - Chronic obstructive pulmonary disease (COPD; including chronic bronchitis and emphysema) is a chronic respiratory condition characterised by shortness of breath, cough and recurrent exacerbations. Long‐term antibiotic use may reduce both bacterial...

Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update
http://ascopubs.org/doi/full/10.1200/JCO.18.00374
Taplitz, R. et. al.

Sep 3rd, 2018 - Antibacterial and antifungal prophylaxis is recommended for patients who are at high risk of infection, including patients who are expected to have profound, protracted neutropenia, which is defined as < 100 neutrophils/µL for > 7 days or other ri...

STRIVERDI® RESPIMAT® (olodaterol) Prescribing Information
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203108s000lbl.pdf

STRIVERDI RESPIMAT Inhalation Spray is a long-acting beta2-adrenergic agonist indicated for: The long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), inclu...

PERJETA® (pertuzumab)
https://www.perjeta.com/hcp/breast-cancer.html

Learn about PERJETA®, indicated for early and metastatic HER2 positive breast cancer. Indications: Metastatic Breast Cancer. PERJETA® (pertuzumab) is indicated for use in combination with Herceptin® (trastuzumab) and docetaxel for the treatment of...

see more →

Patient Education  83 results see all →